Previous 10 | Next 10 |
Akero Therapeutics (NASDAQ: AKRO ) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket. More news on: Akero Therapeutics, Inc., Atreca, Inc., Personalis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Agilent (NYSE: A ) has agreed to acquire privately held BioTek Instruments for $1.165B ($1.05B net with anticipated tax benefits). More news on: Agilent Technologies, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
Highlights: Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis BioTek is a recognized leader for plate-readers and imaging systems with complementary offerings to...
COPENHAGEN, DENMARK and ARMONK, NY: 2 July 2019 --- Rapid adoption of TradeLens across the global shipping supply chain continues as Hapag-Lloyd and Singapore-based Ocean Network Express (ONE) Pte. Ltd announced they will join the blockchain-enabled digital shipping platform, jointly ...
Investment Thesis We have a Buy rating on Agilent ( A ). We like its growth prospects including its new products and growing markets. We love its financials, particularly its pristine balance sheet and cash generative ability as well as its impressive margin expansion. We think that the re...
Agilent Technologies Inc. (NYSE: A) today introduced its first new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress , being held June 22–26, 2019 in Vancouver, Canada. The Agilent ...
Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts, and the latest edition may be found here . However, since this list is only produced once per month, the data in it can quickly get out of date. Fu...
New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases Agilent Technologies Inc. (NYSE: A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufact...
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA ® (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand...
News, Short Squeeze, Breakout and More Instantly...
Agilent Technologies Inc. Company Name:
A Stock Symbol:
NYSE Market:
Agilent Technologies Inc. Website:
MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA ® , a MAGE-A4-directed engineered T-Cell Receptor (TCR) therapy is being considered Agilent Technologies Inc. , (NYSE: A) today announced that it has received FDA a...
2024-08-01 15:15:03 ET William Blair analyst issues OUTPERFORM recommendation for A on August 1, 2024 01:31PM ET. The previous analyst recommendation was Outperform. A was trading at $143.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Technology helps high-throughput labs operate more efficiently Agilent Technologies Inc. (NYSE: A) today announced it has acquired Sigsense Technologies , a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operatio...